Stocktoria
Silence Therapeutics plc SLN
Silence Therapeutics plc financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $559,000 | $43.3M | $31.6M |
| Gross profit | $344,000 | $31.4M | $18.8M |
| R&D expense | $67.8M | $67.9M | $56.9M |
| Operating income | -$91.1M | -$63.3M | -$64.4M |
| Income tax | $11,000 | $845,000 | $956,000 |
| Net income | -$88.6M | -$45.3M | -$54.2M |
| EPS (diluted) | $-0.63 | $-0.33 | $-0.49 |
| Operating cash flow | -$62.3M | -$67.6M | -$49.5M |
| Free cash flow | -$62.3M | -$67.9M | -$49.5M |
| Cash & equivalents | $11.3M | $121.3M | $68.8M |
| Total assets | $131.4M | $202.6M | $119.4M |
| Total liabilities | $69.1M | $68.6M | $97.5M |
| Shareholders' equity | $62.3M | $134.0M | $22.0M |
Growth · year-over-year · Revenue CAGR -86.7%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | -98.7% | +36.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.